ANGPTL8 protein-truncating variant and the risk of coronary disease, type 2 diabetes and adverse effects

Pyry Helkkula, Tuomo Kiiskinen, Aki S. Havulinna, Juha Karjalainen, Seppo Koskinen, Veikko Salomaa, FinnGen, Mark J. Daly, Aarno Palotie, Ida Surakka, Samuli Ripatti
doi: https://doi.org/10.1101/2020.06.09.20125278

Article usage

Article usage: June 2020 to July 2025

AbstractFullPdf
Jun 2020471086
Jul 2020105052
Aug 202074037
Sep 202068035
Oct 202047034
Nov 202043024
Dec 202027026
Jan 202146116
Feb 20215429
Mar 202159310
Apr 202184216
May 20216338
Jun 202158610
Jul 202133313
Aug 20212449
Sep 202126120
Oct 202120025
Nov 202118113
Dec 20212312
Jan 202221510
Feb 20221603
Mar 20221707
Apr 20221714
May 20221908
Jun 20222005
Jul 20221510
Aug 20221326
Sep 20222306
Oct 20222805
Nov 20221603
Dec 20221305
Jan 20231302
Feb 20231014
Mar 20231112
Apr 20232317
May 20231319
Jun 2023941
Jul 2023603
Aug 202315135
Sep 2023844
Oct 20231012
Nov 202323170
Dec 20231204
Jan 2024513
Feb 2024822
Mar 20241448
Apr 202410410
May 2024434
Jun 2024921
Jul 2024602
Aug 2024321
Sep 20241358
Oct 20249168
Nov 20241828
Dec 20241303
Jan 20251116
Feb 20255238
Mar 202524298
Apr 20252557
May 20252269
Jun 2025291110
Jul 20251159
Back to top
Posted June 12, 2020.
Download PDF

Supplementary Material

Data/Code
Email
ANGPTL8 protein-truncating variant and the risk of coronary disease, type 2 diabetes and adverse effects
Pyry Helkkula, Tuomo Kiiskinen, Aki S. Havulinna, Juha Karjalainen, Seppo Koskinen, Veikko Salomaa, FinnGen, Mark J. Daly, Aarno Palotie, Ida Surakka, Samuli Ripatti
medRxiv 2020.06.09.20125278; doi: https://doi.org/10.1101/2020.06.09.20125278
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area